Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

被引：0
|
作者：
Gambacorti-Passerini, Carlo [1 ]
Khoury, H. Jean [2 ]
Kantarjian, Hagop M. [3 ]
Lipton, Jeffrey H. [4 ]
Kim, Dong-Wook [5 ]
Schafhausen, Philippe [6 ]
Matczak, Ewa M. [7 ]
Leip, Eric [8 ]
Noonan, Kay [9 ]
Bruemmendorf, Tim H. [6 ,10 ]
Cortes, Jorge E. [3 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Seoul St Marys Hosp, Seoul, South Korea
[6] Univ Canc Ctr Hamburg, Hubertus Wald Tumor Ctr, Hamburg, Germany
[7] Pfizer Inc, New York, NY USA
[8] Pfizer Inc, Cambridge, MA USA
[9] Pfizer Inc, Groton, CT 06340 USA
[10] RWTH Aachen Univ Hosp, Aachen, Germany
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
    Hochhaus, Andreas
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Deininger, Michael W.
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil P.
    Kantarjian, Hagop M.
    Guilhot, Francois
    BLOOD, 2013, 122 (21)
  • [22] Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM)
    Cortes, J. E.
    Kantarjian, H.
    Bruemmendorf, T.
    Khoury, H. J.
    Kim, D.
    Turkina, A.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Gambacorti-Passerini, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study
    Bruemmendorf, T. H.
    Gambacorti-Passerini, C.
    Kindler, T.
    Saussele, S.
    Kim, D. W.
    Goh, Y. T.
    Dyagil, I
    Pagnano, K.
    Batai, A.
    Turkina, A. G.
    Leip, E.
    Purcell, S.
    Leone, J.
    Viqueira, A.
    Cortes, J. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 70 - 71
  • [24] Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update
    Brummendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Kim, Dong-Wook
    Goh, Yeow Tee
    Dyagil, Iryna
    Pagnano, Katia B.
    Batai, Arpad
    Turkina, Anna G.
    Aguiar, Jean M.
    Leip, Eric
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [25] Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)
    Wang, Jianxiang
    Huang, Xiaojun
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    LEUKEMIA & LYMPHOMA, 2013, 54 : 3 - +
  • [26] Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study.
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    Goh, Yeow Tee
    Yilmaz, Musa
    Klisovic, Rebecca B.
    Purcell, Simon
    Viqueira, Andrea
    Leip, Eric
    Gambacorti-Passerini, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 4-year (y) update
    Larson, Richard A.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kim, Dong-Wook
    Jootar, Saengsuree
    Le Coutre, Philipp D.
    Reiffers, Josy
    Pasquini, Ricardo
    Goldberg, Stuart L.
    Clark, Richard E.
    Kemp, Charisse N.
    Fan, Xiaolin
    Menssen, Hans D.
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase
    袁婷
    China Medical Abstracts(Internal Medicine), 2020, 37 (02) : 111 - 112
  • [30] Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up
    Gambacorti-Passerini, C.
    Cortes, J. E.
    Kim, D.
    Kantarjian, H.
    Khattry, N.
    Lipton, J. H.
    Powell, C.
    Harris, P.
    Countouriotis, A. M.
    Brummendorf, T. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345